NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free KRTX Stock Alerts $329.83 0.00 (0.00%) (As of 04/1/2024) Add Compare Share Share Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99Volume5 shsAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice Target$293.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Karuna Therapeutics alerts: Email Address Karuna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside10.9% Downside$293.92 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$3.17 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.96) to ($7.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.06 out of 5 starsMedical Sector902nd out of 909 stocksPharmaceutical Preparations Industry419th out of 422 stocks 1.2 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageKaruna Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KRTX. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Karuna Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,172,350.00 in company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.96) to ($7.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 9.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More KRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRTX Stock News HeadlinesApril 22, 2024 | bizjournals.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 9, 2024 | msn.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)March 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 260.000 putFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 330.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 280.000 putFebruary 14, 2024 | businesswire.comKARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTXJanuary 31, 2024 | finance.yahoo.comKaruna Therapeutics (KRTX) Rose on Acquisition AnnouncementJanuary 29, 2024 | msn.comKaruna’s KarXT tops Evaluate’s most anticipated drug listJanuary 22, 2024 | msn.comBristol-Myers almost lost Karuna buyout to third partyJanuary 19, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Karuna Therapeutics, Inc. (KRTX)January 12, 2024 | finance.yahoo.comChief Medical Officer Stephen Brannan Sells 15,000 Shares of Karuna Therapeutics IncDecember 31, 2023 | businesswire.comKARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna ...December 29, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)See More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$293.92 High Stock Price Target$330.00 Low Stock Price Target$225.00 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654,000.00 Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Andrew Craig Miller Ph.D. (Age 42)Founder and President of Research & Development Comp: $835.4kDr. Stephen K. Brannan (Age 68)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 56)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.General CounselMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 66)Senior Vice President of Medical More ExecutivesKey CompetitorsBeiGeneNASDAQ:BGNEDr. Reddy's LaboratoriesNYSE:RDYViatrisNASDAQ:VTRSSarepta TherapeuticsNASDAQ:SRPTUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 85 shares on 3/22/2024Ownership: 0.001%Vanguard Group Inc.Bought 21,201 shares on 3/11/2024Ownership: 8.453%Stephen K BrannanSold 5,000 sharesTotal: $1.59 M ($318.34/share)Wellington Management Group LLPSold 151,462 shares on 3/5/2024Ownership: 2.973%Goldman Sachs Group Inc.Bought 166,001 shares on 3/1/2024Ownership: 0.528%View All Insider TransactionsView All Institutional Transactions KRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price target for 2024? 16 brokers have issued 12 month price objectives for Karuna Therapeutics' stock. Their KRTX share price targets range from $225.00 to $330.00. On average, they predict the company's share price to reach $293.92 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2024? Karuna Therapeutics' stock was trading at $316.51 at the beginning of 2024. Since then, KRTX stock has increased by 4.2% and is now trading at $329.83. View the best growth stocks for 2024 here. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The business's revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.22) earnings per share. What ETFs hold Karuna Therapeutics' stock? ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB).Vanguard Small-Cap Value ETF (VBR). What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.